Tyra Biosciences reports Phase 2 bladder cancer data and completes $400 million financing
+3 new sources since this summary was written
Tyra Biosciences announced initial Phase 2 results for dabogratinib in FGFR3‑altered intermediate‑risk non‑muscle invasive bladder cancer, showing a 79% overall response rate and a 64% complete response rate. The company also completed a $400 million public offering, boosting its cash, cash equivalents and marketable securities to $700.5 million and extending its cash runway to 2030. Management said the financing positions Tyra to advance its dabogratinib 3x3 strategy into Phase 3 trials slated for 2027.
Why it matters
The $400 million raise gives Tyra sufficient capital to fund late‑stage development of dabogratinib, reducing near‑term financing risk for investors. The strong Phase 2 response may increase the likelihood of regulatory approval and future revenue, according to the company’s statements.
Key facts
- 1Initial Phase 2 SURF302 results showed a 79% overall response rate and a 64% complete response rate among 14 participants (n=14). prnewswire.com
- 2Among participants with a single marker lesion (n=8), the 60 mg dose achieved a 100% overall response rate and a 75% complete response rate. prnewswire.com
- 3Tyra completed a $400 million financing in September 2026, led by RA Capital Management. prnewswire.com
- 4Cash, cash equivalents and marketable securities totaled $700.5 million as of September 30, 2026, extending the cash runway through 2030. sec.gov
- 5The company plans to initiate a Phase 3 adjuvant study for dabogratinib in IR NMIBC in 2027, subject to regulatory feedback. sec.gov
- 6Net loss for the quarter was $51.1 million. prnewswire.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.